SPX4,145.19
0.16%Negative
IXIC12,657.56
0.50%Negative
DJI32,803.47
0.23%Positive
STOXX435.72
0.76%Negative
FTSE7,439.74
0.11%Negative
N22528,175.87
0.87%Positive

Cytosorbents Corp

CTSO.OQ

Official Data Partner

Latest Trade: trading higher2.1USD
Change: 0.08
% Change: 3.96%Positive

As of Aug 7 2022. Values delayed up to 15 minutes

Day Range: 1.98 - 2.12
52-Week Range: 1.70 - 9.79

Previous Close: 2.02
Open: 2.00
Volume: 22,707.00
3 Month Average Trading Volume: 5.44
Shares Out (Mil): 43.58
Market Cap: 91.51
Forward P/E: -3.36
Dividend Yield: -99,999.99

Key Statistics

1.75 mean rating - 4 analysts

Sell

Hold

Buy

P/E Excl. Extra Items (TTM): -99,999.99
Price To Sales (TTM): 2.43
Price To Book (Quarterly): 1.92
Price To Cash Flow (Per Share TTM): -99,999.99
Total Debt/Total Equity (Quarterly): 0.00
Long Term Debt/Equity (Quarterly): 0.00
Return On Investment (TTM): -48.04
Return On Equity (TTM): -41.98

2021 (millions USD)

About Cytosorbents Corp (CTSO.OQ)

Company Information

CytoSorbents Corporation is a critical care-focused immunotherapy company. The Company is engaged in the treatment of life-threatening conditions in the intensive care (ICU) and cardiac surgery using blood purification via its polymer adsorption technology. The Company's lead product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy and pancreatitis. Its other products include animal-targeted VetResQ, DrugSorb-ATR and ECOS-300CY. The Company's product candidates under development includes CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent and porous polymer beads.